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Abstract
Anti-depressant therapy is one of the most common treatments for depression. However, the
increasing criticism regarding anti-depressant therapy and increased suicidality has caused both
health care providers and the public to question their widespread use (Lader, 2007). In October
2004, the Food and Drug Administration (FDA) mandated that a black box warning be added to
anti-depressant medications in order to alert patients of increased risk of suicidal thoughts in the
pediatric and adolescent population. This black box warning was expanded further to include
patients between 18 to 24 years-of-age at the direction of the FDA in May of 2007 (Friedman &
Leon, 2007). It has been noted that a common reason patients do not report their symptoms of
depression is due to fear that the physician will recommend an anti-depressant (Bell et al., 2011).
Every year in the United States (U.S.), 30,000 people die of suicide and an additional 650,000
people are treated in emergency departments after attempting suicide (Schreiber, Culpepper, &
Fife, 2012), making it imperative to investigate the link between anti-depressants and suicidality.
Studies which focused on the correlation between anti-depressant therapy and suicidality as well
as studies that looked at additional factors (i.e. genetics, toxicological findings) that could have a
strong impact on suicidality were reviewed. The findings of this project indicate that, in studies
examining whether there is a correlation between anti-depressant therapy and suicidality, there
are too many unknown factors to determine whether anti-depressant therapy is the lone factor
responsible for the development of suicidality in patients. Additionally, there is a great need for
research, particularly in the areas of genetics and toxicology, in order to determine whether these
factors play a role in the development of suicidality.
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Research Based Findings of Anti-depressant Therapy and Suicidality
The Centers for Disease Control and Prevention (CDC) define depression as an affective
disorder characterized by at least five of the following symptoms for a period of two or more
weeks: depressed or sad mood, diminished interest in activities which used to be pleasurable,
weight gain or loss, psychomotor agitation or retardation, fatigue, inappropriate guilt, difficulties
concentrating, or recurrent thoughts of death. Depression not only affects the way an individual
feels, but can also have profound effects on an individual’s relationships as well as work and/or
school performance (CDC, 2011). In fact, depression is currently the number one cause of
disability and missed work in the U.S. (Cancro, 2011) and is also one of the most common
reasons for suicide (Reeves & Ladner, 2010). It is estimated that approximately 20 percent of
women and 12 percent of men in the United States (U.S.) will experience depression during their
lifetime (Porth & Matfin, 2009). Of those who encounter one episode of depression, about 50
percent will experience subsequent episodes of depression (CDC, 2011).
With mental health drawing more attention in both the medical world and the public eye,
much emphasis has been placed on finding the best methods to treat depression. While many
studies have found anti-depressant therapy to be efficacious, the possibility of suicide as an
unfortunate outcome resulting from antidepressant therapy leaves many feeling apprehensive
about their use. Determining whether anti-depressant medications increase the risk of suicidality
has proven both controversial and contradictory. Meanwhile, the emphasis on anti-depressant
associated suicidality may have overshadowed the decrease in the rates of suicide attempts and
completions that have also been associated with anti-depressant therapy. Furthermore, other
factors, such as a history of suicidal ideation or behavior prior to beginning an anti-depressant,
co-morbid psychiatric disorders, and/or substance abuse issues may increase the likelihood of

suicidal ideation while taking anti-depressant medications, but may not be at all related to the
anti-depressant therapy. The objective of this project was to review literature related to anti
depressant therapy and suicidality (including suicidal ideation, suicidal attempts, and suicide
completions) to investigate whether or not treating patients with anti-depressants is linked to
increased or decreased rates of suicidal ideation and/or suicidal behavior. These studies were
also reviewed to determine whether or not other confounding factors that may contribute to
suicidality were considered in the study results. Studies that may support a need for additional
research in regards to anti-depressants and suicidality (i.e. toxicological levels and genetic
factors) were also reviewed.
Purpose
Suicide is a tragic and unfortunate outcome for patients struggling with psychiatric
illness...it is “the ultimate endpoint” (Dolgin, 2012, p. 190). The psychiatric illnesses associated
with the highest risk of suicide are: depression, anxiety disorders (including panic disorder and
post-traumatic stress disorder), alcoholism, substance abuse, bipolar disorder, schizophrenia,
personality disorders, and delirium (Schreiber, Culpepper, & Fife, 2012). Additionally, a prior
history of self-harm and/or psychiatric hospitalization significantly increases the risk for suicide
(Lader, 2007). In fact, prior history of suicide attempts have been identified as the strongest
single predictor of future suicide attempts (Olmer, Iancu, & Strous, 2009).
In addition to personality characteristics or co-morbid mental illnesses associated with
suicidality, there are also measureable demographic factors that increase the risk of suicide. Men
are four times as likely as women to die of suicide. Suicide rates in those aged 65 years and
older occurred at a rate of 14.3 per 100,000 people, versus the 11.3 suicides per 100,000 people
of all ages. Suicide rates of non-Hispanic white men aged 85 years and older occurred at a rate
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of 47 per 100,000 pbople (NIMN, 2012). From this data, one could surmise that in order for
research studies to properly analyze the link between suicide and anti-depressant therapy with
that of the general population, the study should include four times as many men as women, and
should also include men over the age of 65 years and 85 years-of-age. The methods that studies
use to depict the agds of the participant population (which are often as a mean with a standard
deviation) make it difficult to determine the exact demographics of the study population.
Studies have shown that the initiation of anti-depressants reduced suicidal thoughts or
behavior in patients who were previously experiencing suicidal thoughts (Simon, 2012).
However, warnings that there may be a direct correlation between anti-depressant use and
suicidality have left some medical professionals and patients skeptical about their safety (Lader,
2007). This skepticism can lead to the under-diagnosis and under-treatment of psychiatric
illness, which is adVerse to positive patient care and outcomes.
The facts regarding untreated psychiatric illness and suicide seem to be obscured as the
controversy over the correlation between anti-depressant use and suicidality continues to swirl.
For example, one observational study performed over a 38 year period found that 14 percent of
the participants committed suicide. This suicide rate is an astounding 27 times greater than that
of the general population (Simon, 2012). In order to provide for the best interests of the patient,
it is important to determine whether or not studies that have focused on this correlation have
considered confounding factors, such as those factors listed as high risk for suicide previously in
the paper. This project will analyze the outcomes of research studies that focus on the
correlation between anti-depressant therapy and suicidality to determine if there could be other
factors which contribute to suicidality in participants who reported experiencing suicidality after
initiating anti-deprekant therapy.
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Significance
Anti-depressants are largely considered an efficacious treatment of depression, anxiety,
and other mental health disorders. However, the FDA warnings issued in 2004 and 2007
regarding anti-depressant use and increased suicidality in the pediatric, adolescent, and young
adult population seems to have decreased the rates of both diagnosing depression and treating
patients with anti-depressants (Simon, 2012). This is unfortunate because the meta-analysis
which led to the FDA warning included no completed suicides, infrequent suicide attempts, and
only found clinical significance related to the correlation between anti-depressants and
suicidality when suicidal ideation and possible suicidal ideation were added as endpoints in the
study (Valuck, Orton, & Libby, 2009). The reluctance among some prescribers when
considering whether or not to use anti-depressants as a treatment is a huge concern (Lader,
2007), especially since studies have found anti-depressant treatment to be associated with
significantly lower fates of suicidal mortality when compared to untreated depressed patients
(Simon, 2012).
Suicide is the tenth leading cause of death worldwide (Schreiber, Culpepper, & Fife,
2012) and the third eading cause of death in people under 45 years-of-age in the U.S. (Dolgin,
2012). Of those who complete suicide, more than 95 percent have at least one psychiatric
diagnosis (Schreiber, Culpepper, & Fife, 2012). In order to diagnose and treat patients
appropriately, it is imperative to clarify the risks involved where anti-depressants and suicidality
are concerned. However, despite the unknowns related to suicide and anti-depressants, in 2011,
the National Institutes of Health (NIH) spent only about 0.6 percent of their total budget on
suicide prevention, and a little more than twice that on suicide research in comparison to the 10%
of the agency’s budget that was utilized to research HIV/AIDS (Dolgin, 2012).
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Some professionals have suggested that the FDA consider utilizing epidemiologic data as
a way to determine whether or not medications have the outcomes sought in the general
population. For example, one psychiatrist petitioned to have the FDA consider 31 observational
studies showing that lithium “can reduce the risk of suicidal behaviors in individuals with bipolar
disorder or other major mood disorders by as much as 80 percent” (Dolgin, 2012, p. 192). The
FDA stated that, in order to consider epidemiologic data, there would need to be “an
overwhelming amount of observational data” showing that lithium did reduce suicide (Dolgin, p.
192). What the FDA recommended was performing randomized trials that consisted of 5,000
participants exposed over a time period of two years or more.
The medical field (and the general public) needs accurate information on whether anti
depressant therapy, in itself, causes suicidality, or whether other confounding factors cause
suicidality in patients who are being treated with anti-depressants. Finding answers to the
question of suicidality related to anti-depressants may be difficult, however, due to the rarity of
suicidal behaviors in clinical trial participants, an inadequate amount of information related to
people who attempt suicide in the real-world population, and “ethical issues involved in studying
this severe outcome with randomized, placebo controlled trials,” (Valuck, Orton, & Libby, 2009,
p. 1069). In fact, drug trials involving psychiatric medications exclude patients experiencing
suicidal thoughts from their studies due to ethical concerns (Dolgin, 2012). However, despite the
controversy regarding the correlation between anti-depressants and suicidality and the ethical
issues that limit research parameters in this area, providers and patients alike have a right to
know the risk factors associated with anti-depressants and what other factors may contribute to
suicidality so, together, they can make an informed decision about the treatment plan.
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Theoretical Framework
There are many factors that play a part in an individual’s suicidality. While some of these
factors are easy to determine by reviewing a patient’s medical record (i.e. comorbid medical and
mental illness, prior history of suicide attempts or psychiatric hospitalizations, or comorbid
substance abuse), some factors (such as brain derived neurotrophic factor levels or genetics) are
more difficult to detect. The biopsychosocial theory fits the purpose of this project because there
are many components that can play a role in the development of suicidality during anti
depressant treatment, and all factors must be considered while assessing what role, if any, anti
depressants play in suicidality.
This project includes several studies which emphasize different factors that can play a role
in the development of suicidality among patients. This is necessary in order to establish an
understanding that the development of suicidality is multi-factoral. It is not something that can
be accurately measured by a study which analyzes one specific factor (i.e. genetic factors
involved in suicidality or a correlation between anti-depressant use and suicidality). Therefore,
determining whether or not anti-depressant therapy increases the risk for suicidality is difficult
because there are numerous factors that play a role in this.
By using the biopsychosocial theory to guide this project, the author reviewed studies that
analyzed the correlation between anti-depressant therapy and suicidality. However, studies that
analyzed other factors, such as genetics, that may play a role in suicidality were also reviewed.
Three studies in which serum toxicology levels were tested in individuals who committed suicide
were reviewed to determine what percentage of these individuals had anti-depressants in their
system. The only competent way to look at suicidality is to look at the information from a multi
faceted view. It is difficult to get a broad view of how anti-depressant therapy correlates with
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suicidality when many studies do not take the other multiple possible reasons for suicidality into
account.
Definitions
There are several key terms pertinent to this project. These terms are defined below. It is
important for readers to understand the differences between these terms in order to better
understand how each has been used for the purpose of this project.
■ Depression: An affective disorder characterized by at least five of the following symptoms
for a period of two or more weeks: depressed or sad mood, diminished interest in
activities which used to be pleasurable, weight gain or loss, psychomotor agitation or
retardation, fatigue, inappropriate guilt, difficulties concentrating, or recurrent thoughts
of death (CDC, 2011).
■ Suicidality: A term inclusive of suicidal thoughts, preparatory acts, suicide attempts and
suicide completions
■ Suicide attempt: An act that is carried out with the intention of resulting in one’s own
death
■ Suicide completion: An act that is committed with the intention of, and has resulted in,
one’s own death
■ Suicidal ideation: Thoughts of killing oneself
■ Non Suicidal Self Injury: Self-injurious bodily injury performed to damage the body
surface, but not done as a way to commit suicide. Examples include cutting, burning, or
hitting oneself (APA, 2012).
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Review of the Literature
Several research studies have attempted to provide answers to the question of whether or
not there is a correlation between anti-depressant use and suicide and/or suicidal
thoughts/behaviors. However, study results have proven controversial. Some studies have found
that anti-depressants do cause suicidal thoughts/behaviors while other studies have found just the
opposite. Outcomes of other studies have referenced an increase in suicidal thoughts, but a
decreased rate of both suicidal behavior and mortality due to suicide where anti-depressant
treatment is utilized.
Observational studies attempting to link antidepressants to suicidality may be skewed
solely by confounds of indication due to the increased risk in suicide in the population being
studied (Isacsson, Holmgren, & Ahlner, 2005; Isacsson, Holmgren, & Ahlner, 2009; Cougnard et
al., 2009), while randomized controlled trials often exclude potential participants experiencing
suicidal ideation. Furthermore, the short period of follow-up and stringent inclusion and
exclusion criteria of randomized controlled trials make it difficult to test theories on a population
of participants similar to the population of patients treated with antidepressants in real world
conditions. Furthermore, it is often difficult to draw a conclusive theory in regards to the
outcome of randomized controlled trials, due to the short treatment duration and small number of
participants in the studies (Cougnard et al., 2009).
In addition to the mental health diagnoses listed previously in the paper as increasing the
risk for suicidality, studies have also identified an association between genetic factors and
suicidality. Perroud et al. (2009) found that a genetic polymorphism in the brain derived
neurotrophic factor (BDNF) gene could also be a strong genetic factor contributing to increased
suicidality. The authors further noted that several studies have found, “a decreased level of
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BDNF in the hippocampus and prefrontal cortex (PFC) of suicide victims and in the
cerebrospinal fluid (CSF) and plasma of suicide attempters (Perroud et al. 2009, p. 2523).” In
addition, Olmer, Iancu, and Strous, (2012) found that, with separate interventions of
psychotherapy and antidepressant therapy, and a combination of the two interventions, the
incidence of suicide is highest in the month prior to initiation of treatment and the risk declines
steadily over the next six months.
Rucci et al. (2011) studied whether 318 participants who were randomly assigned into
treatment with either the serotonin reuptake inhibitor (SSRI) escitalopram or psychotherapy
(IPT) would experie nee emergent suicidal ideation (ESI) during the course of a 20 week period
in which they were ollowed. The participants were selected from two University Outpatient
Clinics (University Of Pittsburg and the outpatient clinic of the Osperdale Santa Chiara of the
University of Pisa) between April 2003 and April 2008. Of the 318 participants, 210 were
female and 108 were male. All participants were between 18 and 66 years of age and had a
diagnosis of a non-psychotic major depressive episode. Ninety participants were experiencing
their first episode of depressive illness, while 201 reported having two or more episodes of
depression. Additio nally, suicidal thoughts were present in 59 of the participants at the time of
pretreatment interview, while one participant noted having a suicide plan. The strengths of this
study are as follows participants were referred from outpatient clinics (and not based from the
general population) who were randomized assigned to treatment groups; the outcomes of two
commonly used intejrventions for the treatment of major depressive episodes were compared;
participants experiencing suicidal thoughts at the baseline interview were included in the study.
The limitations of the study were: a small participant pool (N=318); the participant pool
consisted of 72 percent females; the mean age was relatively young (38.3 years); the study did

13

not include patient over 64 years old or those under age 19; the study only utilized one
medication as a therapeutic intervention which limits the results of the study from use in other
drug populations; patients with psychotic depression, active suicidal ideation with a plan, current
alcohol or drug abuse, current eating disorders, and newly diagnosed and unstable physical
illness were excluded from the study.
The findings of this study were interesting because of the 21 participants who had a
history of previous suicide attempts, none developed ESI during treatment. Of the 231
participants who were free of any suicidal thoughts at baseline, 32 exhibited ESI at some point
during the follow-up period. Twenty-two of the participants who developed ESI had been
assigned to the IPT group, while ten had been assigned to the escitalopram group. Time from
initiation of treatment to development of ESI was as follows: less than four weeks (N=13);
between five and eight weeks (N=9); and after eight weeks (N=10). The study also found that
time to suicidal ideation was significantly longer for those in the SSRI group versus the IPT
group. Patients who developed ESI during the study were able to be managed successfully by
the study protocol, and referral to a higher level of care was only required in two cases (Rucci et
al., 2011).
Mulder, Joyce, & Frampton, (2008) scrutinized whether treating patients, who were
either currently experiencing suicidal ideation or had a history of suicide attempts with anti
depressants, reduced those thoughts/behaviors over time. The study focused on 195 patients who
were referred by psychiatric emergency services, community mental health centers, and general
practitioners from 1993 to 2001. The inclusion criteria were: at least 18 years of age, primary
current diagnosis of major depression; willing and able to give informed consent; treatment with
antidepressants was deemed to be appropriate management. Patients who were breastfeeding,
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pregnant, likely to become pregnant, had a major medical disorder that could complicate
assessment or treatment, severe drug or alcohol dependence; and a history of mania,
schizoaffective disorder, or schizophrenia were all exclusionary criteria.
The participants of the above study were 57.4% were female and the mean age was 32.2
(SD 11.4) years. Most of the patients denied any suicidal ideation, however, 34.6% of
participants reported at least moderate suicidal ideation. Additionally, 23.3% (39 patients) had
reported a suicide attempt within six months prior to treatment, while 12 participants reported
more than one suicide attempt in the previous six months. Participants met DSM-III-R criteria
for at least one of the following disorders: bipolar II disorder (9%); melancholia (44%); atypical
depression (8%); recurrent depression (52%); chronic depression (64%) (Mulder, Joyce, &
Frampton, 2008).
The participants were then randomly assigned to receive a treatment of either fluoxetine
or nortriptyline. They were interviewed and asked about whether they had experienced suicidal
ideation in the past 4 days. Their answers were rated as none, occasional, moderate, and
regular. At weeks 3 6,9,13, 20, and 26, participants were asked about any suicide attempts since
the previous visit. After six weeks of treatment, participants continued on their current
medications if they had responded to it. Those who did not respond to the initial medication
were switched to the other medication group. If participants did not respond to the second
medication, the two medications were combined, and subsequently, the clinician was free to use
whatever medication he/she felt was clinically indicated. The patients were divided into three
groups based on their treatment outcome; patients who recovered and remained well until the
six-month assessment; patients who either achieved remission or recovered but subsequently
relapsed; patients with persistent depression (Mulder, Joyce, & Frampton, 2008).
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Of the 195 participants initiated into the study, 176 remained at the time of the six month
follow up. Ten participants dropped out.. .nine left the area, and one withdrew without treatment
and later committed suicide. Sixty-six percent of the patients had continued to take fluoxetine or
nortriptyline, while 24 patients had either elected to stop the medications or had found it
intolerable (however they did remain in the study). Throughout the six month course of
treatment, 29 patients attempted suicide. This is in comparison to the 51 patients who reported
attempting suicide at least once in the six months prior to the study. The study further found
that that antidepressant treatment reduced suicidal ideation by 33% in the first three weeks of
treatment and 38% over the course of six months, and that the number of suicide attempts
dropped by 50 % in comparison to the six month period prior to treatment. None of the patients
without suicidal ideation or suicide attempts in the six months prior to treatment who developed
ESI during the study (N=5) attempted suicide (Mulder, Joyce, & Frampton, 2008).
Similarly, Se emuller et al. (2009) performed a prospective naturalistic study that included
1,014 participants w ho were recruited from seven German psychiatric university hospitals. The
participants were between 18 and 65 years of age, were willing and able to sign informed
consent, and had a diagnosis meeting criteria for any major depressive episode confirmed using
the Structured Clinical Interview for DSM-IV. This study analyzed 18 predictors: “HAMD total
score; gender; age (also dichotomized >45 or over <_45); years since first diagnosis; suicide
attempt immediately before hospitalization; suicide in first and second-degree relatives; alcohol
abuse or dependency ; any substance abuse or dependency; any comorbid personality disorder;
diagnosis of any bipolar disorder; number of hospitalizations; akathisia; presence of childhood
trauma; treatment resistance; family status; children; native language German” (Seemuller et al.
p. 183). The HAMD score in most of these patients indicated they were either moderately or
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severely depressed upon admission. Of the 1,014 study participants, 137 had attempted suicide
immediately prior to being admitted to the hospital. During treatment, 10 participants attempted
suicide and two participants completed suicide. The study found that 14.4% of participants
experienced worsening of suicidal ideation, compared to 90 percent of participants who reported
improvement in suicidal ideation. The study additionally identified that patients under age 45
years are more likely to experience ESI. When compared to that general population, suicide
rates among study participants were much higher; however, these rates were only slightly
elevated in comparison to those commonly found in RCTs. Furthermore, 22 potential risk
factors for extended emergence suicidal ideation were determined, but two independent
statistical methods identified age, treatment resistance, number of hospitalizations, presence of
akathisia, and comorbid personality disorder.
Olmer, Iancu, and Strous (2012) performed a retrospective study in which they reviewed
adult patients admitted to the Beer Yaakov Mental Health Center from 2000 to 2007 with a
diagnosis of major depressive disorder (MDD). The aim of the study was to analyze whether
antidepressants have a significant relationship in suicide attempts. Upon review of the charts
from patients hospitalized following a suicide attempt, 103 patients met all of the inclusion
criteria, which were: no diagnosis of bipolar spectrum disorder; diagnosis of major depressive
disorder; and a recorded suicide attempt within four weeks prior to hospitalization. The study
population consisted of 69 women and 34 men with a mean age of 49.21 years (SD 14.56 years).
The study found no significant correlation between antidepressants and suicide attempts.
However, the researchers also suggested that SSRIs may be less effective in treating suicidal
depressed patients who are hospitalized in comparison to antidepressants that have effects on
multiple neurotransmitters.
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Cougnard et al. (2008) examined whether antidepressants decrease suicide. The
participants were broken into three age groups (children and adolescents 10 to 19 years of age,
adults 20 to 64 years old, and elderly patients 65 years of age or older) diagnosed with major
depression. Data was extracted from both published studies and databases of the French general
population. The number of suicides induced or avoided by antidepressant therapy and no
antidepressant therapy was then estimated. The researchers estimated that antidepressant therapy
would prevent 31.9% of suicides in depressed subjects over one year in comparison to no
antidepressant therapy in the 10 to 19 year age group, 32.2% of suicides in adult depressed
subjects, and 32.3% of suicides in elderly depressed patients. The finding that antidepressants
act as a protective factor against suicide can also be carried into the general population. While
this study did include a large population of subjects, the simplified model constructed for the
purpose of this study is a weakness.
When it comes to the link between antidepressant use and suicidality, there are many
unknown factors. Many studies rely solely on the report of the patient when determining
whether or not they are taking antidepressants. However, some toxicology studies have found
that only a small number of suicide victims have traces of antidepressants in their system.
Isacsson, Holmgren, and Ahlner (2005) tested this theory. They believed that if SSRIs posed an
increased risk of suicide, the medication should be found more often in toxicology reports. This
study analyzed the toxicology reports of 14,857 suicide cases in Sweden between the years 1992
and 2000. The study also looked at 4,301 deaths by uncertain causes to ensure that deaths by
overdose were not overlooked. Seventy-one percent of the cases studies were men and the
median age was 49 years. The study group was then compared to a control group consisting of
26,422 cases determined to be death by accident or natural causes. The control group consisted
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of 73% men and a median age of 55 years. The study also analyzed 52 suicides in children under
15 years-of-age and 326 cases of suicide in adolescents between the age of 15 and 19.
The study by Isacsson, Holmgren, and Ahlner (2005) found that only 7 of the 52 cases of
suicide in children under age 15 were positive for any kind of anti-depressant, and no cases were
positive for SSRIs, compared to 5 cases of the 998 total persons in the control group under 15
years of age. In the age group of 15 to 19, 13 of 326 suicide cases were positive for
antidepressants. Only six of these cases were positive for SSRIs. This is compared to anti
depressant detection in five cases (three of which were SSRIs) of the 577 total cases in the 15-19
control group. Antidepressants were detected in only 13% of children, 4% of adolescents, and
23% of suicide cases among all age groups. As a result of this study, the researchers reported that
SSRIs were detected at lower rates than other anti-depressants in suicide victims, and suggested
that under-treatment with antidepressants is still an issue.
Isacsson, Holmgren, and Ahlner (2009) repeated a similar study in Sweden to include
suicides (N=16,937), natural deaths (N=12,181) occurring between 1995 and 2005. The mean
age of the suicide group and control group combined was 50.6 years, with 70.8% being male.
During the period from 1995 to 2005, the number of suicides exposed to antidepressants
increased by 46% while the suicides decreased by 18.6%. Among the control group, the use of
anti-depressants increased by 109%. The authors suggested that antidepressants reduced the risk
of suicide by 43%.
A smaller study of 253 persons conducted by Cortes et al., (2011) found similar results.
This retrospective study was conducted on suicide victims aged 24 years-of-age or younger in
Miami-Dade County Florida from 1990 to 2007. The researchers then reviewed demographic
data, psychosocial factors, suicide characteristics, and toxicology reports. The study found that
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approximately 90% (N=228) had no trace of antidepressants on review of the serum toxicology
report. Six percent bf these antidepressants were found to be SSRIs. Interestingly, the
researchers also noted several other substances in these patients upon review of the toxicology
report, including: 31.6% (N=80) showed a presence of alcohol, while 17.8% (N=45), opioids
6.7% (N=17), hallucinogens 1.2% (N=3), benzodiazepines 12.3% (N=31); other types 13%
(N=33); and unknown 5.9% (N=15). Ninety seven patients (38.3%) had no substances shown on
the toxicology report. The suicide victims studied were 85% male and 53.4% were Hispanic.
Women were more frequently found to have positive results for antidepressants on the
toxicology reports than men.
Leon, et al., (2004) conducted a small toxicological study on 66 suicide victims less than
18 years-of-age between 1993 and 1998 evaluated whether or not serum blood samples revealed
the presence of anti-depressants. Because the longest acting anti-depressant, fluoxetine, has a
half-life of 21 hours, 12 victims (who lived for 3 days or more following their suicidal act) were
excluded from the study, leaving 54 persons available for toxicological testing. The age range of
the deceased ranged from 10 to 17 years-of-age with seven being younger than 13 years of age.
The ethnicities of the deceased were evenly split between Hispanics, African Americans, and
Caucasians. Additionally, 75 percent of the deceased were males. The toxicological results
found that paroxetine was not present in any of the suicide victims, two screened positive for the
presence of imipramine, and two screened positive for fluoxetine. While the study is small, it
does confirm, as do the other toxicological reports discussed above, that the large majority of
suicide victims are not taking anti-depressants at the time of their death.
In addition to serum toxicology levels, genetic predisposition is another factor that is not
commonly analyzed in studies questioning the link between antidepressants and suicidality. A
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study by Perroud, et al., (2009) examined whether emergent suicidal ideation during
antidepressant treatment could be driven by genetic factors. The researchers selected nine genes
involved in neurotrophic, serotonergic, and noradrenergic pathways. The participants (N=796)
were then treated with antidepressants and were studied for emergence of suicidal ideation and
genetic variances over a 12 week time frame. Participants were included in this study if they met
criteria for an episode of major depression that was of at least moderate severity. Patients were
randomly assigned to either escitalopram or nortriptyline treatment groups. However, patients
that had a contraindication to taking one of the medications were assigned to the other anti
depressant group. Participants were 18 to 72 years of age. Participants with a primary substance
misuse or primary organic disease, pregnancy or lactation, current treatment with an
antipsychotic or mood stabilizer, history of hypomanic or manic episode, mood incongruent
psychotic symptoms, or a first degree relative with a bipolar disorder diagnosis or schizophrenia,
were excluded from the study.
In their study, Perroud et al. (2009) found that a larger number of males experienced
suicidal ideation when taking nortriptyline if they had the A allele compared to the C allele. The
study also found that “variants in the genes encoding BDNF and its receptor (NTRK2) were
associated with an increase in suicidal ideation during antidepressant treatment in subjects
suffering from major depressive disorder” (Perroud et al., p. 2524). The researchers, “found an
even stronger effect for an interaction between the known functional BDNP-LCPR GT (n)
polymorphism and SNPs in the 3’ region of NTRK2” (Perroud et al., p. 2524). The small
sample size of participants is a weakness of this study. In addition, the limited number of
participants under 25 and over 65 years-of-age made it impossible to make any assumptions on
how genetic polymorphisms may affect these age groups.
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Ecological studies have analyzed the number of anti-depressant prescriptions provided to
a population against changes in suicide rates. Studies conducted since 2005 have consistently
shown an inverse correlation between the number of anti-depressants prescribed and the number
of completed suicides (Castelpietra, et al., 2008; Henriksson, et al., 2006; Korkeila, et al., 2007).
One study conducted in Finland, a country where two-thirds of the population suffer from a
depressive disorder, analyzed the number of anti-depressants prescribed and the number of
suicides between 1994 and 2001. There were a total number of 1,387 completed suicides in
1994 compared to 1,204 completed suicides in 2001. During that same time period, the number
individuals prescribed anti-depressants increased from 140,438 in 1994 to 272,370 in 2001. The
study found that an increase in the number of anti-depressants prescribed was significantly
associated with a decrease in suicide rates (16 percent in men and 14 percent in women) after
gender, age, and region were taken into account (Korkeila et al., 2007).
A similar study done among individuals living in the Fruili Venezia Giulia region of Italy
(which is the region of Italy found to have the highest rate of suicide in the country) between the
years of 1997 and 2006 found that the use of anti-depressants increased from 11.9 individuals
users per 1,000 inhabitants in 1997 to 56.7 individual users per inhabitants in 2006. During that
time frame, suicides rates decreased from 13.8 per 100,000 in 1997 to 9.1 per 100,000 in 2001.
This equates to a relative suicide risk reduction of 35 percent in women and 34 percent in men
(Castelpietra, et al., 2008). Another ecological study in done in Jamtland county, Sweden from
1995-2002 focused on educating general practitioners as a way to improve treatment in patients
struggling with depression in Jamtland county, Sweden, but also analyzed whether the program
had an impact on the number of anti-depressants prescribed and suicide rates. The study found
that sales of anti-depressants increased 161% in Jamtland County between 1995 and 2002. With
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regard to anti-depressant use and suicide rates, the study found that the increased use of anti
depressants were associated with a decreased rate of suicide of 30 percent and 47 percent in men
and women of Jamtland County, respectively (Henriksson, & Isacsson, 2006).
All three of the ecological studies discussed above found that the antidepressants
prescribed were primarily from the SSRI class (Castelpietra, et al., 2008; Korkelia et al., 2007;
Henriksson & Isacsson, 2006). Two of the three studies noted that more women than men were
prescribed anti-depressants (Henriksson, & Isacsson, 2006) and all three studies found that more
men committed suicide than women (Castelpietra, et al., 2008; Korkelia et al., 2007; Henriksson
& Isacsson, 2006). One main weakness of all three studies is that none examined serum blood
levels of those who had committed suicide for the presence of anti-depressants.
A cohort study performed in Finland included 100 percent of people hospitalized for
suicide attempts between 1997 and 2003. The study population was 15,390 patients, including
7,466 males and 7,924 females. The researchers calculated the relative risk of suicide attempts,
suicide completions, and overall mortality of patients being treated with anti-depressants versus
no treatment with anti-depressants. The anti-depressants included were TCA (amitriptyline or
doxepin), SSRI (fluoxetine, citalopram, paroxetine, sertraline, or fluvoxamine), and SNA
(mianserin, mirtazapine, or venlafaxine). The results of the study found that, while there was an
increased risk of suicide attempts in patients taking anti-depressants versus no treatment with
antidepressants, there was no increased risk of suicide completions. Additionally, the study
found a decreased mortality rate, particularly in the rate of cardiovascular-related deaths
(Tiihonen, et al., 2006).
Furthermore, the American College of Neuropsychopharmacology (ACNP) formed a task
force that reviewed several studies, including the meta-analysis which was conducted by the
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FDA and later resulted in the black box warning for anti-depressants, epidemiologic studies,
RCTs and post-mortem toxicological studies. The ACNP found that, while the FDAs meta
analysis does show a small increase in suicide attempts or suicidal thinking in youths, the effect
varies across the RCTs reviewed in the meta-analysis. The ACNP further determined that, while
the variance could be due to a difference between medications, it is also possible that the
variance could be due to an error in measurement. The epidemiologic and post-mortem studies
as well as cohort surveys reviewed by the ACNP did not support an increase in suicidal acts or
suicide, and instead found a possible beneficial effect between anti-depressants and suicidality.
The ACNP also surmised that, based on the post-mortem toxicological youth studies, only a
small number of youth who commit suicide are taking anti-depressants at the time of suicide
(Mann, et al., 2006).
Methods
A systematic literature search was conducted to identify randomized controlled trials and
epidemiologic studies indexed between 2005 and 2012. Cochrane Library, CINAHL (Headings),
PubMed (MeSH), and Psychlnfo (Thesaurus) were utilized to conduct the search. The search
terms utilized for the purpose of this project were “antidepressive agents” and “‘suicide” or
“suicidal ideation.” Two separate searches were performed in CINAHL (Headings), PubMed
(MeSH), and Psychlnfo (Thesaurus). The initial search included the search terms previously
listed, but limited the search to only randomized control trials. The second search included the
initial search terms, but limited the search to epidemiologic studies.
Cochrane Library was first searched for studies using these terms. This search returned
26 results, 21 of which were published after 2004. Of those results, three were found to be of
particular interest for the purposes of this project.
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CINAHL (Headings) was searched next using the same terms. The search limited to
randomized controlled trials returned 323 results. Limiting the results to PDF full text only
returned 50 results. Excluding studies published prior to 2005 further confined results to 40
studies. Including only peer reviewed articles limited the results to 34. Further review of these
results determined that four of the studies were pertinent to the topic of this paper. A second
search was then performed in CINAHL (Headings) to include prospective studies. This search
returned 607 results. Further limiting this search to PDF full text only returned 99 results.
Including only studies published between 2005 and 2012 further confined the number of results
to 72 articles. Including only those studies that had been peer reviewed and available in the
English language limited the results to 65. Review of the resulting prospective studies revealed
that six were appropriate for further review for this paper.
The PubMed database was then searched using the same terms (“antidepressive agents”
and '‘suicide” or “suicidal ideation”). The search was further limited to include randomized
controlled trials (as a publication type). This search returned 78 results. Delimiting the search
further to publications dates between 2005 and 2012 returned a total of 65 articles. Limiting the
articles to full text only further limited the number of articles to 63. Further review of these
articles determined that six were pertinent to this project. One of the articles found pertinent to
the project was a task force review of multiple study types (meta-analysis, RCTs, epidemiologic,
and post-mortem toxicology studies) that examined the correlation between anti-depressants and
suicidality among children and adolescents (Mann, et al., 2006). A second search in PubMed
using the terms returned 35 results when the criteria was further delimited to full text
prospective studies published between 2005 and 2012. Of these studies, two were appropriate
for the purpose of this paper. A third search (using the same terms) was also conducted in
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PubMed (MeSH) to include the term “epidemiologic studies.” The initial search returned 480
results. Further limiting the results to full-text articles published between 2005 and 2012
returned 351 results. Of the studies reviewed, 12 were found pertinent to the topic of this paper.
A search of the Psychlnfo (Thesaurus) database was then searched using the terms
“antidepressant drugs” and “suicide” or “suicidal ideation” and “clinical trials” returned 32
results. Further limiting the search to articles published between 2005 and 2012 returned 30
results. When the author further delimited results by adding criteria for peer reviewed and full
text articles only, seven articles were returned. Further review of these articles revealed that two
were appropriate for use in this project. There were no full text results for prospective studies
related to the key terms searched in Psychlnfo (Thesaurus).
The author also reviewed the reference lists of the articles chosen for inclusion in the
paper, and utilized three studies from those lists. One of the studies chosen was published in
2004; however, it provided important post-mortem toxicological evidence of youth suicide and
anti-depressant use and thus, was included in the study. All of these articles focused on the
presence of serum antidepressant level during post-mortem autopsy. Kim Gregg, RN, CNS, was
consulted to review and provide recommendations and guidance of this project. The hopes is
that this project will affect a change in clinical practice by revealing whether studies that
question the link between anti-depressants and suicidality have taken confounding factors into
consideration when reporting their results. If that is not the case, then whether or not
antidepressants alone increase the risk for suicide and or suicidality should be open for
deliberation.
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Results
A copy of both the written paper and the Power Point presentation for this project was
provided to Registered Nurses and Psychiatrists who are members of the Integrated Behavioral
Health Team at Mayo, Clinical Nurse Specialists who are members of the Psychiatry Department
at Mayo, and student colleagues in the Mental Health Nurse Practitioner Program at the
University of North Dakota for feedback. Colleagues provided positive feedback regarding the
types of studies that were reviewed for the project. The colleagues noted the tremendous impact
keeping meticulous medical records (such as those depicted in the studies performed in Finland
and Sweden) could have on both medical research and patient outcomes. Most were particularly
interested in toxicological and genetic findings from the studies reviewed.
Discussion and Implications for Nursing
According to the National Institute of Mental Health (NIMH), the U.S. suicide rate was
11.3 deaths per 100,000 in the general population in 2007 (NIMH, n.d.). Since more than 95%
of people who die of suicide suffer from depression or other mental disorder (Schreiber,
Culpepper, & Fife, 2012), it can be deduced that the suicide rate is much higher in the sub
population of those who are struggling with mental illness in comparison to the general
population. Controlled studies completed with a goal of showing whether there is a correlation
between anti-depressants and suicide or suicidal thoughts and/or behaviors on the sub-population
mentioned above often exclude patients who are at higher risk for developing suicide or suicidal
ideation/behaviors due to ethical issues (Tiihonen et al., 2007). It would make sense that the
exclusion of participants at higher risk for suicide from controlled studies would, in turn, cause
controlled studies to have lower rates of suicide or suicidal ideation/behavior in comparison to
epidemiologic studies (Howland, 2006). However, several epidemiologic studies have shown
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that treatment with anti-depressants decrease the rate of suicide (Tiihonen, et al., 2006; Olfson,
Marcus, & Shaffer, 2006; Castelpietra, et al., 2008).
It is crucial to delineate any confounding factors (other than the use of anti-depressants)
that may contribute to an increase in suicide and or suicidal thoughts/behaviors in these studies
in order to authentically state that anti-depressant therapy is the sole cause of a participant’s
suicidal thoughts and/or behaviors. Making claims that anti-depressants increase suicide and/or
suicidal thoughts/behaviors without fully exploring every other plausible explanation is not only
unfounded, but creates a falsity throughout the medical field and in the public eye that can
substantially impact patient treatment and outcomes.
There is concern among both health care providers and the lay public with regard to the
correlation between anti-depressant therapy and suicidality. While the FDA warning label was
based on a meta-analysis that reviewed the correlation between anti-depressant use and
suicidality, no completed suicides were reported during this study (Valuck, Orton, & Libby,
2009). There are too many unknowns to determine whether or a direct correlation between
antidepressant treatment and suicidality exists. Genetic factors, comorbid medical or
psychological disorders, and history of prior self-harm/suicide attempts are just a few of the
unknown factors that could be influencing the study outcomes. These factors could play a role
in suicidal thoughts or behaviors in both adolescents and adults, and while these thoughts and
behaviors may occur in conjunction with anti-depressant treatment, it should not be an indication
that the anti-depressants caused the thoughts or behaviors to occur.
One study of suicide attempts and non-suicidal self-injury in adolescents (ages 12 to 18
years-of-age) with treatment resistant depression found that 47.4% reported non-suicidal selfinjury at baseline. National surveillance data also indicates that approximately 6.3% of high
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school students attempt suicide (Rosenbaum-Asarnow et al., 2011). It is difficult to show that
anti-depressants cause increased suicidality in adolescents, where self-harm behavior is common.
Further research is needed to determine whether there is a link correlating antidepressants
and suicide levels. The lack of studies that include drawing toxicological serum levels alone can
impact the study findings because patient report alone is used to determine whether or not
participants are taking their anti-depressants. It is of particular importance to obtain serum anti
depressant levels in children, adolescents, and adults who participate in self-harm, attempt
suicide, or complete suicide, especially since post-mortem studies have consistently found that
over 80 percent of depressed adult suicide victims are not taking anti-depressants at the time of
their death (Mann, et al., 2006). Another area for possible research is genetic studies. Testing
for factors, such as BDNF, may also prove helpful in decreasing suicidality in patients in the
future.
As nurses, there are many things that we can do to promote mental wellness among our
patients while promoting health policy in our communities. Continued education both among the
public and among the health care community is essential in order to recognize and accurately
treat patients with mental illness. Advocating for our patients by helping to increase the
diagnosis and treatment of mental illness in the outpatient setting is one step that could have a
very positive impact on patient outcome. Another positive step would be creating awareness
programs in our middle schools and high schools, where the risk for self-harm behavior and
suicide attempts is high. In order to effectively improve patient outcomes where mental illness is
concerned, it is essential to evaluate each community on an individual basis. High risk areas in
which there is potential for improved outcomes should be identifies, and programs tailored to
those high risk areas should be developed integrated into health care policy.
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Summary/Conclusions
The correlation between mental illness and suicidality is a huge health concern. While
many studies have been done to identify whether anti-depressant treatment is directly correlated
with an increase in suicidality, these studies do not take into account many of the confounding
factors that could increase suicidality independent from anti-depressant use. Ecological studies
have consistently found a decrease in suicide rates with a corresponding increase in anti
depressant use. Toxicological studies have also consistently found that the majority of patients
who commit suicide do not have anti-depressants present in their system at the time of death.
However, few studies include toxicological serum levels to ensure compliance with anti
depressants. Some studies have also correlated a decreased level of BDNF with increased
suicidality, yet few studies have considered low BDNF levels as a possible variable for increased
suicidality.
The studies reviewed for evidence of whether or not anti-depressants increase suicidality
in patients do not account for many of the factors that increase the risk for suicidality
independent from anti-depressant use. Because of this, it is not possible to say whether or not
there is a correlation between the use of anti-depressants and suicidality. Furthermore, it is
important to separate the terms of self-injurious behavior, suicide attempt, and suicide
completion instead of using the term suicidality to discuss the effects anti-depressants have on
behaviors. There is evidence that the risk of suicidality increases in the initial four weeks
following treatment for depression (whether it is psychotherapy or medication based), but then
decreases significantly after that time. It is imperative to monitor patients closely for suicidality
after initiating treatment for mental illness. However, the fear that antidepressants may cause
suicidality in some patients should not overshadow the need to treat them. There is strong
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evidence to support that anti-depressant treatment offers long term benefit to patients struggling
with mental illness in relation to suicide risk.
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Appendix A
Research Based Findings of Anti-depressant Therapy and Suicidality: Power Point Presentation

Research Based Findings of AntiDepressant Therapy and Suicidality
Melissa Webster
University of North Dakota

Purpose of the Project
» Review literature related to anti-d ep ressant
therapy and suicidality including:
• Suicidal ideation
Suicide attempts
Suicide completions
►Determine w hether or not confounding
factors that might contribute to suicidality
were considered in the study results
►Review studies that may provide areas
needing additional research (i.e. toxicological
levels and genetic factors)
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Theoretical Framework
* Biopsychosocial model was utilized to guide
this project
> The biopsychosocial model allows fo r a
m ulti-faceted analysis regarding the
reasoning for the developm ent of suicidality
in patients

Methods
► Systematic literature searches were conducted In Cochrane
Library, CINAHL (Headings), PubMed (MeSH), and Psychlnfo
(Thesarus)
* Search terms utilized were ' antidepressive agents" and
"suicide" or “suicidal ideation"
» Search criteria were delimited to full text articles in the
English language with publication dates between 2005 and
2012
► Randomized controlled trials and epidemiological studies (!,«,
cohort, retrospective, or observational) fitting the criteria
above were identified and were further reviewed for
pertinence
»" Review of the reference list of the articles selected for use in
the project were reviewed, and three articles from these
reference lists were utilized in the project
»■ Kim Gregg, RN, CHS, was consulted for guidance throughout
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Mental Illness and Suicide
*

Mental illnesses associated with the highest risk of suicide
include:
* Depression
Anxiety disorders (including panic disorder and PTSD)
Alcoholism
Substance abuse
* Bipolar disorder
Schizophrenia
Personality Disorder

* Delirium

*

(Schr#tb«<\ Culpepper, and Fife, 2012)

Additional factors that increase suicide risk are:
* Prior psychiatric hospitalization
» Prior history of self-harm behavior
(uder. 200n
Prior history of suicide attempts (this is the strongest single predictor
of future suicide attempts )
(Otreer, lancw. & Strous. 20091

Depression
►One of the most common mental health disorders
associated with increased suicide risk
►Defined as an affective disorder characterized by at
least five of the following symptoms for at least
two weeks:
Depressed or sad mood
Weight loss/gain
Fatigue
inappropriate guilt
Psychomotor agitation retardation
Difficulty concentrating
Diminished interest in activities which used to be
pleasurable
Recurrent thoughts of death
(CDC, 2011)
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Depression Statistics
Depression can also profoundly effects an
individual's interpersonal relationships as well as
work and school function
►#1 cause of missed work and disability in U.S
*

(Cantro, 2011)

►Estimated 20% of women and 12 % of men in U.S,
will experience depression during their lifetime
(Porth &Matfin, 2009)

►Of those who experience one episode of
depression, the rate of recurrence is approximately
50%
(CDC, 201 1)

Suicide Statistics
p

Suicide is the third leading cause of death in those
under age 45 in the U.S.
• It is the 10th leading cause of death in the world
(Doigm. 2012)

*

U.S. suicide rate in the general population is
11.3/100,000 people
(NIMH, nd)

►Every year in the U.S. 30,000 people die of suicide
An additional 650,000 are treated in emergency rooms
annually following suicide attempts

►Of those who complete suicide, more than 95%
have at least one psychiatric diagnosis
(Schreiber, Culpepper, & Fife, 2012)

III!
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Suicide Statistics, cont.
> Men are 4xs more likely than women to die of suicide
> Rate of suicide in general public is 11.3 per 100,000 people
* Rate is increased to 14,3 per 100,000 people in men 65 years and
older
Rate is 47 per 100,000 people in non-Hispanic white men aged 85
years and older
(NIMH, 2012)

t Adolescents ages 12 to 18 years of age have suicide attempt
rate of 6.496
Rate of non-suicidal self-injury among adolescents 12-16 is 4 7 ,7 $
(Rosenbaum-Asarnow, et al., 2011)
> One study found that patients with mental illness had a

suicide rate of 27 times greater than that of the general
population
(Simon, 2012 )

im p o rt a n c e o f d e te rm in in g c o rre la tio n
b e tw e e n a n t i- d e p r e s s a n t u s e a n d s u ic id a lity
►Anti-depressants are one of the most common
treatments for depression, anxiety, and other mental
illnesses.
» 2004: The (FDA) mandated a black box warning be
added to anti-depressant medications in order to alert
patients of increased risk of suicidal thoughts in the
pediatric and adolescent population (Friedman & Leon, 2<x>7)
► 2007: FDA mandated that the black box warning be
expanded further to include patients between 18 to 24
years-of-age
*■The mandated warning was based on a meta-analysis
that included no completed suicides and infrequent
suicide attempts
Clinical significance was only found when endpoints
of when suicidal ideation and possible suicidal
(Valuck, Orton, & Libby, 2009)
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impact of FDA Warning
►A common reason that patients do not report
symptoms of depression is the fear an anti
depressant will be recommended
►Decreased both the rates of diagnosing depression
and treating patients with anti-depressants
(Simon, 2012)

► These

negative impacts are unfortunate because
studies have found that anti-depressant treatment
is associated with significantly lower rates of
suicidal mortality
(Simon, 2012)

Literature Review
>

Rucci et al.t 2011
Randomly assigned 318 participants to receive SSRI
(escitalopram) treatment or psychotherapy (IPT) groups
Participants selected from two University Outpatient Clinics
between April 2003 and April 2008
210 female participants, 109 male participants
90 participants were experiencing their first episode of
depression
201 participants had at least 2 depressive episodes
59 participants had suicidal ideation and 1 had a plan at
time of pretreatment interview
The goal of the study was to determine whether or not the
participants in the groups would experience emergent
suicidal ideation (ESI) during treatment

Literature Review
►Rucci et al.f 2011, (Cont.)
Strengths:
* Participants were referred from clinic setting, not from the general
population:
* Two commonly used interventions (S5RI and IPT treatments) were
compared
* Participants experiencing suicidal ideation were included in the study
> limitations:
* Participant pool was 7 2 * female
* Study did not include those under 19 or over 64 years-of-age
* Results are limited to the use of escitalopram versus other medications
* Patients with a plan to commit suicide, those with psychotic depression,
current alcohol or drug use, or newly diagnosed and unstable physical
ill ness were excluded

Literature Review
> Rucci, et al., 2011
Findings
* None of participants (N=21) who had history of
previous suicide attempts developed ESI during the
study period
* Of 231 participants who denied suicidal thoughts at
baseline, 32 developed ESI at some point during
follow-up. Timeline for ESI development is as
follows:
• Less than 4 w eeks: N * 13
• 5 to 8 w eeks: N=*9
• After 8 w eeks: N * 10

* Time to ESI was significantly longer for the SSRI
group than in the IPT group
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Literature Review
» Mulder, Joyce, & Frampton (2008)
Coal; To determine whether patients who were either currently
experiencing s.i. or had a history of suicide attempts with anti
depressants reduced those thoughts behaviors over time
; 195 participants
Referred from psychiatric emergency services, community mental
health centers, and general practitioners between 1995 and 2001
» Inclusion criteria:

-I S y*tr*-of-ag« or old* r
•primary current diagnosis of major dtprtssion
antid«pr®ssants
-willing and abl* to giv* Informed content
-Met criteria for bipolar II disorder, melancholia, atypical depression, recurrent
depression, or chronic depression
< Exclusion criteria:

-Irtastfetding/pregnant i ltaty to become pregnant
-Major medical disorder that could complicate treatment
-Sever* drug alcohotdependence
-History of mania schizoaffective disorder.'sOiizophrenia

Literature Review
» M ulderjoyce, & Frampton (2008), cont.
►Statistics:
57,496 female
Mean age 32.2 years (Standard Deviation 11.4)
34.696 reported at least moderate suicidal ideation
39 patients reported a suicide attempt within the 6 months
prior to treatment
12 participants reported more than one suicide attempt
within the 6 months prior to treatment
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Literature Review
* Mulder, Joyce,& Frampton (2008), cont.
* Randomly assigned to groups for treatment with either
nortriptyline or fluoxetine
Participants were followed for 6 months
They were asked if they experienced suicidal ideation in the
past 14 days.
They were evaluated for suicide attempts since the beginning
of the study six times in the 6 month period
Participants who did not respond to the initial medication at 6
weeks after treatment were switched to the other medication
group
If the patients didn’t respond to the second medication, they
were treated with a combination of the two mediations
if there was no response with combination treatment, the
clinician used whatever medication they felt was indicated

Literature Review
►MulderJoyce,

&

Framptom, (2008) Results:

Patients were divided into three groups based on their treatment
outcome
Patients who recovered and remained well until the six-month
assessm ent
Patients who either achieved remission or recovered but subsequently
relapsed
* Patients with persistent depression
176 of the 195 participants remained at the 6 month follow-up
* 9 participants left the area, 1 participant withdrew without treatment
and later committed suicide
* 66K of patients remained on either fluoxetine or nortriptyline at 6
month follow-up
* 24 patients had stopped the medication because they either elected
to or found it intolerable
* 29 patients attempted suicide (compared to the 51 participants who
attempted suicide in the 6 months prior to the study)
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Literature Review
i M ulder,Joyce, & Fram ptom , 2 0 0 8 - Results (cont).
Suicidal ideation was reduced by 33% in the first 3
weeks of treatm ent* 38% over course of 6 months
The number of suicides dropped to 50%comparedto
6 month period prior to treatment
None of the 5 participants who had no suicidal
ideation or suicide attempts in the six months prior to
treatment but developed ESI during the study
attempted suicide

Literature Review
> Seemuller, et al. (2009)
Naturalistic study that included 1,014 participants
Participants were recruited from 7 German psychiatric
university hospitals
®Inclusion criteria:
* 18-65 years of age
* Willing and able to sign informed consent
* Diagnosis meeting criteria for any major depressive episode

13 7 of the participants had attempted suicide
immediately prior to hospitalization
10 participants attempted suicide and two
participants completed suicide during treatment
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Literature Review
►Results: Seem uller.etal. (2009)
14.4% of participants experienced worsening of
suicidal ideation
Patients under 45 years-of-age were more likely to
experience ESI
Suicide rates among study participants were much
higher than the general population
Suicide rates were only slightly elevated compared
with that of other RCTs

Literature Review
» Olmer, lancu, and Strous (2012)
Retrospective study
Reviewed adult patients admitted to the Beer Yaakov Mental
Health Center from 2000-2007 with diagnosis of MDD
Coal of study was to analyze whether anti-depressants
have a significant relationship in suicide attempts
* Inclusion criteria:
* Diagnosis of MDD
* Recorded suicide attempt within four weeks prior to
hospitalization
* Exclusion criteria:
* Diagnosis of bipolar spectrum disorder
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Literature Review
> Olrrter, lancu, and Strous (2012), cont
> Study population
* 103 patients, including 69 women and 34 women
* Mean age of 49.21 (standard deviation oOf 14.56 years)

> Results
No significant correlation between anti-depressants and
suicide attempts
Researchers also suggested that SSRls may be less effective
in treating hospitalized suicidal depressed patients than
anti-depressants that may have effects on multiple
neurotransmitters

Literature Review
>
* Cougnard, et al. (2008)
►Aim of the study was to analyze whether anti
depressants decrease suicide
* Data for the study was extracted from both
published studies and databases of the French
General population
* Participants broken into 3 age groups:
* Children and adolescents ages 10-19 years of age
* Adults 20-64 years of age
* Patients 65 years of age or older
►Number of suicides either induced or avoided by
anti-depressants was estimated
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Literature Review
* Cougnard, et a!. (2008), cont,

» Results:
In the 10-19 year age group
* Ami-depressant therapy would prevent an estimated
31.9% of suicides in depressed subjects over one year in
compared to no anti-depressant therapy
In the 20-64 year age group
* Anti-depressant therapy would prevent an estimated
32.2% of suicides in depressed subjects over one year in
compared to no anti-depressant therapy
• In the age group over 65 years-of-age
* Anti-depressant therapy would prevent an estimated
32.3% of suicides in depressed subjects over one year In
compared to no anti-depressant therapy

Literature Review
» Isacsson, Holmgren, and Ahlner(2005)
i Tested the theory that traces of anti-depressants
would be found commonly in suicide victims if
anti-depressants did increase suicide risk
►Toxicology reports of 14,857 suicide cases in
Sweden from 1992-2000 were analyzed
►Study also examined a control group of 26,422
who died of natural or accidental causes
i Median age in suicide group was 49 years old vs.
55 years old in control group
» 52 suicides in children under 15 and 326 suicides
in adolescents aged 15-19 were also analyzed
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Literature Review
*■Isacsson, Holmgren, and Ahler (2005), cont.

> Findings
» Under 15 years of age:
* 7 of 52 cases were positive for ami-depressants, although
none were positive for SSRis, vs. 4 cases among the 998
controls in this age group

* Age 15-19
* 13 of 326 suicide cases were positive for anti-depressants,
only 6 of the 13 cases were positive for SSRIs
* 5 cases among the 577 controls were positive for anti
depressants (3 were positive for SSRis)

* Overall outcome
* Anti-depressants detected in 13% of children, 4% of
adolescents, and 23% of suicide victims among all age
groups

literature Review
> Isacsson, Holmgren, and Ahlner (2009)
* Study similar to 2005 was performed
* Evaluated the number of anti-depressants prescribed in
1995 and 2005 to the number of suicides that occurred
in 1995 and 2005
* 16,937 suicides in Sweden between 1995-2005 were
examined and compared it to a control group of 12,181
natural deaths
* Findings:
Anti-depressant use increased by 46% in the suicide group
while suicides decreased by 18.6%
In the control group, the use of anti-depressants increased by
109%
Anti-deoressants reduced suicide risk by 43%

50

Literature Review
* Cortes etal. (2011)

» Retrospective study of suicide victims 24 years-of-age
or younger in Miami Dade County, Florida from 1990►253 cases were analyzed
* Demographic data, suicide characteristics, psychosocial
factors, and toxicology reports were reviewed
►Demographics
* 85% men (N=215)
Average age 20.3 years (standard deviation of 2.6 with a range
of 11 -24 years)
* 53.4% (N=l 35)Hispanic; 26.9% (N=68) Caucasian; f 5,4%
(N=39) African American; 4.3% <N =ll)of other ethnic origin
70% (n=l 77) were living w/ family

Literature Review
►C ortes,etal., 2011
►Psychiatric history
91% (N=231) had undetermined family history of mental
illness
4% (N-9) had documented family history of at least one
family member with mental Illness
Almost 45% (N=l 12) of cases had a personal history of
mental illness
8% (N—21) of cases known to have a history of treatment
for mental illness
* 19% (N=49) had a known legal history
• 76% (N=l 92} were known to have had stressors of some
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Literature Review
i Cortes, et al., 2011
i Toxicology Report
90% (N=228) did not have any kind of anti-depressants
present
6% (N=15) were positive for SSRI, SNRI, TCCA, or other type
of anti-depressant
31.6% (N=80) positive for alcohol
17.8% (N=45) positive for stimulants
6.7% (N=17) positive for opioids
1.2%fN=3) positive for hallucinogens
12.3% fN=31) positive for benzodiazepines

Literature Review
> Cortes et al., cont
► Findings
Women and those at least 19 years of age were found to
have been using antidepressants compared to men
1 3% women were positive for presence of antidepressants
compared to 4% of men
90% of the sample did not have any kind of antidepressant
in their system
No difference in detection of anti-depressants was found
between Hispanic and Non-Hispanic cases
* Alcohol was present in 31.6% of the cases
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Literature Review
►Leon, et al. (2004)
Small toxicological study of 66 suicide victims less than 18
years-of-age between 1993-1998
Study evaluated whether or not anti-depressants were
present in serum blood samples of suicide victims
* Victims who lived for 3 days or longer after the suicidal act
were excluded as anti-depressant levels would be
undetectable after that time
* 12 were excluded as a result, leaving 54 available for serum testing

* Age range was 10 to 1 7 years of age (7 were younger than

13)
Ethnicity was evenly divided between Hispanic, African
American, and Caucasian
* 7596 were males

Literature Review
> Leon, et al. (2004)
> Findings:
Paroxetine was not present in any of the cases
Imipramine was present in two cases
Fluoxetine was present in two cases
The large majority of victims were not taking anti
depressants at the time of their death
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Literature Review
i Perroud,2009
►Examined whether emergent suicidal ideation (ESI)
during antidepressant treatment could be driven by
genetic factors
►9 genes that involved neurotrophic, serotonergic,
and noradrenergic pathways were selected
► 796 participants were treated with antidepressants
and studied for genetic variances and ESI during a
12 week time frame

Literature Review
* Perroud, et al., (2009), cont.
* Inclusion criteria:
* 18-72 years of age
Must have met criteria for an episode of major depression that
was of at least moderate severity

» Exclusion criteria:
First degree relative with a diagnosis of bipolar disorder or
schizophrenia
* Primary substance misuse
Primary organic disease
Pregnancy or lactation
Current treatment with an antipsychotic or mood stabilizer
History of hypo manic or manic episode
* Mood incongruent psychotic symptoms
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Literature Review
* Perroud, et ai. (2009} com.
► Method
Participants were randomly assigned to either escitalopram or
nortriptyline treatment groups
Patients that had a contraindication to one of the medications
were assigned to the other medication group
♦ Findings

A larger number of males experienced suicidal ideation when
taking nortriptyline if they had the A allele compared to the C
allele
Variants in the genes encoding BDNF and its receptor (NTRK2)
were associated with an increase in suicidal ideation during
antidepressant treatment in subjects suffering from major
depressive disorder
The BDNP-LCPR GT (n) polymorphism and SNP in the 3* region
of MTRK2 was found to have an even stronger relation to
suicidal ideation

Literature Review
*■

Korkeilaetal., 2007
Analyzed the number of anti-depressants prescribed and
compared it to the number of completed suicides in Finland
between 1994 and 2001
• 1994;
* individuals prescribed anti-depressants= 140,438
* Completed suicides = l .387

• 2001:
* Individuals prescribed anti-depressants =272,370
* Completed suic»des=1,204
• Findings:
* An increase in the number of anti-depressants prescribed
was significantly associated with a decrease in suicide
rates (16% In men and 14% in women}

55

Literature Review
►Castelpeitra, etal. (2008)
* Study in Italy between 1997 and 2006
► Looked at the number of anti-depressants prescribed
compared to number of completed suicides
► Anti-depressant use increased from 11.9/1,000 individuals in
1997 to 56.7/1,000 individuals in 2006
* Suicide rates decreased from 13.8 100.000 in 1997 to
9.1/100,000 in 2006
► This represents a suicide risk reduction of 35% in women and
34% in men

Literature Review
* Henriksson & Isacsson, (2006)
» Study done in jamtland County Sweden between 19952002

* Focused on educating general practitioners to improve
treatment for patients struggling with depression, but
also analyzed if the program impacted the number of
individuals prescribed antidepressants and how the
number of antidepressant prescriptions impacted the
suicide rate.
» Results:
Antidepressants increased 161% between 1995 and 2002
The increased use of antidepressants correlated with a
decreased rate of suicide <30% in men and 47% in women)
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Literature Review
►Common findings among Castelpietra, et al„
(2008), Korkeliaet al., (2007) and Henriksson&
Isacsson, (2006):
The majority of the anti-depressants prescribed were SSRis
Ail three studies noted more men than women completed
suicide
Two of the three studies noted that more women than men
were taking antidepressants (Castelpietra et al., 2008;
Korkelia et al., 2007)
Main weakness of all three studies is that they did not
perform toxicological testing for presence of anti
depressants in suicide victims

Literature Review
»• Tiihonen etal., (2006)
* Cohort study done in Finland that included 100% of
people hospitalized for suicide attempts from 19972003
* Goal was to calculate the relative risk of suicide
attempts/completions and overall mortality of patients
being treated with antidepressants vs. no
antidepressant treatment
*■Study included 15,390 patients (7,466 men and 7.924
females)
► Antidepressants included in the study were: TCA
(amitriptyline or doxepin),SSRI (fluoxetine, citalopram,
paroxetine, sertraline, or fluvoxamine), and SNA
, orvenlafaxine)
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Literature Review
►Tiihonenet al„ <2006)
►Results:
There is an increased risk of suicide attempts with the use
of anti-depressants, however, there was no increased risk
of suicide completions
Also found that antidepressants increased mortality rate
overall, particularly where cardio-vascular related deaths
are concerned

Literature Review
►Matin et a!., (2006)
American College of Neuropharmacology (ACNP)
formed a task force that reviewed several studies,
including the meta-analysis that resulted in the
FDA black box warning
« Epidemiologic studies, RCTs, and post-mortem
toxicological studies were also reviewed
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Literature Review
» Mann et al., (2006)
» Findings
The FDA meta-analysis did show a small increase in
suicide attempts or suicidal thinking in youths, but
added that the findings of the RCTs reviewed for the
meta-analysis varied
* The ACNP noted that the variance between these RCTs could
be due to a difference between medications, or it could be
due to an error in measurement

Postmortem and cohort surveys
* No evidence to support an increase in suicidal acts or suicide
and instead found a possible beneficial effect between anti
depressants and suicidaiity
■ Postmortem toxicological youth studies found only a small
number of youth who commit suicide are taking anti
depressants at the time of suicide

Implications for Nursing
r What can nurses do to improve patient outcomes?
Educate ourselves about mental illness and pass our
knowledge on to both the public and other health care
providers in order to increase the diagnosis and treatment
of mental illness
Identify populations at high risk for mental illness in the
community
Oevelop programs geared towards the recognition and
treatment of mental illness in order to improve patient
outcomes

Conclusion
►Concern regarding a correlation between anti
depressant use and suicidality have caused a
decrease in the diagnosis and treatment of
depression and has also caused some patients to be
fearful of trialing antidepressants
» The meta-analysis utilized by the FDA to implement
the mandatory black box warning included no
completed suicides, infrequent suicide attempts, and
only found clinical significance related to a
correlation between antidepressant use and
suicidality when the endpoints of suicidal ideation
and possible suicidal ideation were added as
endpoints (Valuck, Orton, & Libby, 2009)

Conclusion
» The term suicidality should be broken into terms including
suicidal ideation, suicide attempt, and suicide completions
because there is evidence to support that antidepressant
therapy is associated with significantly lower rates of suicidal
mortality compared to untreated depressed patients (Simon,
2012 ).
» Confounding factors (i.e. prior history of self-harm or suicide
attempts, history of psychiatric hospitalization, comorbid
personality disorders or substance dependence) may increase
the risk for developing suicidality, but these are not
commonly accounted for in studies
* Few studies include toxicological findings, however, post
mortem toxicological studies have consistently found that few
suicide victims have antidepressants in their system at the
time of their death {Isacsson, Hoigren. & Abler, 2005; Cortes et at.,
2011; Leon et ai., 2004)
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Conclusion
►Genetic factors, such as decreased levels of BDNF, may
also contribute to suicidal ideation in patients
* There is evidence to support that suicidality is increased
in the initial four weeks following treatment, but that
the risk decreases significantly after that time.
* Overall, antidepressants have been found to have a
protective effect against suicide
* There is not enough evidence to definitively say that
antidepressants afone cause suicidality
► Further research is needed to determine if there is any
correlation between anti-depressants and suicidality
There is a need for further research in the areas of
genetics and toxicological studies
particular attention should be paid to the end point of
all studies performed
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